Adjusted Study Protocol: Within-Subject Paired-Eye Design Comparing Pilocarpine 0.1%, Phentolamine 0.75%, and Combination Therapy for Cyclopentolate Reversal in Children
Launched by MANSOURA UNIVERSITY · May 31, 2025
Trial Information
Current as of September 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at ways to help children who need eye exams and glasses prescriptions by reversing the effects of certain eye drops that cause the pupils to widen and make it hard to focus. The study will compare three different treatments: pilocarpine, phentolamine, and a combination of both. The goal is to find a method that can reduce glare and improve near vision more quickly, making the eye exam experience better for kids.
To be eligible to participate in this study, children must be between 5 and 12 years old and undergoing a procedure that involves the use of eye drops that cause temporary blurred vision. Parents will need to give their permission for their child to join, and the trial is not currently recruiting participants. If selected, children will receive one of the treatments being studied and will help researchers understand which method works best for reversing the effects of the eye drops.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children between 5 and 12 years undergoing cycloplegia
- Exclusion Criteria:
- • Patient refusal
About Mansoura University
Mansoura University is a prestigious academic institution located in Egypt, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, it leverages its extensive resources and expertise in various fields of healthcare to facilitate innovative research initiatives aimed at improving patient outcomes. The university collaborates with a network of healthcare professionals and researchers to conduct high-quality clinical trials, focusing on addressing critical health challenges through rigorous scientific methodologies. Its dedication to ethical research practices and adherence to regulatory standards underscores its role as a leader in the medical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported